Patients with advanced head and neck cancer is at high risk of recurrence at the primary site
or in the neck. Part of normal treatment is to treat such patients with chemotherapy and
radiation. The chemotherapy can include Erbitux. The purpose of this study is to treat such
patients with an additional agent, Torisel. This study tests the doses of Torisel that can be
safely administered together with radiation and chemotherapy.